CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma

Trial Profile

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Mesothelioma; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CONFIRM
  • Most Recent Events

    • 05 Jun 2018 Current enrolment at 01 Feb 2018 was 63, according to the trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 Sep 2017 Trial design of the study presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top